RM Global Partners

RM Global sources primarily through its cross-border advisory practice. The firm's broker-dealer relationships with Korean and Japanese corporate acquirers surface companies seeking strategic exit or growth-partnering paths. This advisory flow provides proprietary deal intelligence that feeds the firm's principal investing pipeline, often giving it early access to Israeli-founded and US-based life-science platforms before broader institutional processes begin.

RM Global operates as a hybrid. It is registered as a broker-dealer and provides M&A advisory, divestiture, and corporate partnering services, primarily for cross-border transactions. Simultaneously, it deploys proprietary capital into early-stage and growth-stage companies, with a focus on life sciences and technology. This dual-track model is relatively uncommon among boutiques that typically choose one or the other.

The firm invests from early-stage seed and startup rounds through late-stage growth, including PIPE and recapitalization transactions. In practice, RM Global often enters at the bridge point where a US or Israeli company needs institutional capital to fund international expansion or prepare for a strategic exit to an Asian buyer. The firm's advisory insights inform its stage-flexible approach.

RM Global concentrates on healthcare services, biotechnology, medical devices, digital health, and enterprise software with AI/ML applications. Within healthcare, the firm has historically prioritized companies developing biologics discovery platforms and digital health infrastructure. Its technology practice emphasizes enterprise platforms that address Asian market demand for automation and clinical workflow tools.

RM Global conducts direct investments and co-investments, principally through its own balance sheet and deal-by-deal structures. There is no public record of the firm acting as a limited partner in third-party venture or private equity funds. Its model depends on direct exposure to companies where it can also advise on strategic outcomes.